Vistagen announced it has agreed to acquire Pherin Pharmaceuticals Inc., to bolster its efforts on discovery and development of therapeutics to treat a range of psychiatric and neuropsychiatric conditions.
According to a Vistagen release, the company will acquire Pherin Pharmaceuticals for approximately 12.4 million shares of Vistagen common stock and a nominal amount of cash. Once the sale is complete, Vistagen is slated to gain Pherin’s entire pherine pipeline, including full ownership of intellectual property rights to its two most advanced drug candidates, PH94B — currently in